Neonatal bone marrow transplantation of ADA-deficient SCID mice results in immunologic reconstitution despite low levels of engraftment and an absence of selective donor T lymphoid expansion

Blood

Volumn 111, Issue 12, 2008, Pages 5745-5754

  Carbonaro, Denise A ^a,b   Jin, Xiangyang ^a   Cotoi, Daniel ^a   Mi, Tiejuan ^c   Yu, Xiao Jin ^a   Skelton, Dianne C ^a   Dorey, Frederick ^b   Kellems, Rodney E ^c   Blackburn, Michael R ^c   Kohn, Donald B ^a,b  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DEAMINASE; BUSULFAN; CD19 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CESIUM 137; IL2RG PROTEIN, MOUSE; INTERLEUKIN 2 RECEPTOR GAMMA;

ADENOSINE DEAMINASE DEFICIENCY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; BONE MARROW TRANSPLANTATION; CELL PROLIFERATION; CHIMERA; CONTROLLED STUDY; ENGRAFTMENT; FEMALE; IMMUNE RESPONSE; KNOCKOUT MOUSE; LYMPHOCYTE COUNT; MALE; MOUSE; NEWBORN; NEWBORN PERIOD; NONHUMAN; NONMYELOABLATIVE CONDITIONING; PRE T LYMPHOCYTE; PRIORITY JOURNAL; T LYMPHOCYTE; TREATMENT OUTCOME; WHOLE BODY RADIATION; ANIMAL; CONVALESCENCE; CYTOLOGY; ENZYME ACTIVATION; GENETICS; GRAFT SURVIVAL; HISTOCOMPATIBILITY; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; METABOLISM; MOUSE MUTANT; MOUSE STRAIN; SEVERE COMBINED IMMUNODEFICIENCY; SURVIVAL RATE; T LYMPHOCYTE SUBPOPULATION;

ADENOSINE DEAMINASE; ANIMALS; ANIMALS, NEWBORN; BONE MARROW TRANSPLANTATION; ENZYME ACTIVATION; GRAFT SURVIVAL; INTERLEUKIN RECEPTOR COMMON GAMMA SUBUNIT; MICE; MICE, INBRED STRAINS; MICE, KNOCKOUT; MICE, SCID; RECOVERY OF FUNCTION; SEVERE COMBINED IMMUNODEFICIENCY; SURVIVAL RATE; T-LYMPHOCYTE SUBSETS; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING;

EID: 47049124096     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-08-103663     Document Type: Article

References (30)

1. Hershfield MS, Mitchell BS. Immunodeficiency diseases caused by adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency. In: Scriver CR, BeaudetAL SlyWS, Valle D, eds. Metabolic and Molecular Bases of Inherited Disease, 8th ed. New York, NY: McGraw-Hill; 2001:2585-2625.
2. Small TN, Freidrich W, O'Reilly RJ. Hematopoietic stem cell transplantation for immunodeficiency diseases. In: Blume KG, Forman SJ, Ap-pelbaum FR, eds. Hematopoietic Stem Cell Transplantation, 3rd ed. Maiden, MA: Blackwell Science; 2004:1430-1442.
3. Buckley RH, Schiff SE, Schiff Rl, et al. Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. N Engl J Med. 1999;340:508-516.
4. van Leeuwen JE, van Tol MJ, Joosten AM, et al. Relationship between patterns of engraftment in peripheral blood and immune reconstitution after allogeneic bone marrow transplantation for (severe) combined immunodeficiency. Blood. 1994; 84:3936-3947.
5. Tjonnfjord GE, Steen R, Veiby OR Friedrich W, Egeland T. Evidence for engraftment of donor-type multipotent CD34+ cells in a patient with selective T-lymphocyte reconstitution after bone marrow transplantation forB-SCID. Blood. 1994; 84:3584-3589.
6. Haddad E, Le Deist F, Aucouturier P, et al. Longterm chimerism and B-cell function after bone marrow transplantation in patients with severe combined immunodeficiency with B cells: a single-center study of 22 patients. Blood. 1999; 94:2923-2930.
7. Wakamiya M, Blackburn ME, Jurecic R, et al. Disruption of the adenosine deaminase gene causes hepatocellular impairment and perinatal lethality in mice. Proc Natl Acad Sci USA. 1995;92:3673-3677.
8. Migchielsen AAJ, Breuer ML, van Roon MA, et al. Adenosine deaminase deficient mice die perina-tally and exhibit liver-cell degeneration, atelectasis and small intestinal cell death. Nat Genet. 1995;10:279-287.
9. Blackburn MR, Wakamiya M, CaskeyCT Kellems RE. Tissue-specific rescue suggests that placental adenosine deaminase is important for fetal development in mice. J Biol Chem. 1995; 270:23891-23894.
10. Blackburn MR, Datta SK, Kellems RE. Adenosine deaminase-deficient mice generated using a two-stage genetic engineering strategy exhibit a combined immunodeficiency. J Biol Chem. 1998;273: 5093-5100.
11. Blackburn MR, Vollmer JB., Thrasher JL et al. Metabolic consequences of adenosine deaminase deficiency in mice are associated with defects in alveogenesis, pulmonary inflammation, and airway obstruction. J Exp Med. 2000:192: 159-170.
12. Blackburn MR, Aldrich M, Vollmer JB, etal. The use of enzyme therapy to regulate the metabolic and phenotypic consequences of adenosine deaminase deficiency in mice. J Biol Chem. 2000;275:32114-32121.
13. Carbonaro DA, Jin X, Petersen D, et al. In vivo transduction by intravenous injection of a lentiviral vector expressing human ADA into neonatal ADA gene knockout mice: a novel form of enzyme replacement therapy for ADA deficiency. Mol Ther. 2006;13:1110-1120.
14. MortellaroA, Hernandez RJ, Guerrini MM, etal. Ex vivo gene therapy with lentiviral vectors rescues adenosine deaminase (ADA)-deficient mice and corrects their immune and metabolic defects. Blood. 2006;108:2979-2988.
15. Sands MS, Barker JE. Percutaneous intravenous injection in neonatal mice. Lab Anim Sci. 1999; 49:328-330.
16. Yoder MC, Gumming JG, Hiatt K, Mukherjee P, Williams DA. A novel method of myeloablation to enhance engraftment of adult bone marrow cells in newborn mice. Biol Blood Marrow Transplant. 1996;2:59-67.
17. Stack AS, Alatman-Hamadzic SA, Morris PJ, London SD, London L. Polychlorinated biphenyl mixtures (Aroclors) inhibit LPS-induced murine splenocyte proliferation in vitro. Toxicology. 1999; 139:137-154.
18. Wardermann H, BoehmT, DearN, Carsetti R. B-1 a B cells that link the innate and adaptive immune responses are lacking in the absence of a spleen. J Exp Med. 2002;195:771-780.
19. Knudsen TB, Winters RS, Otey SK, et al. Effects of R-deoxycoformycin (pentostatin) on intrauterine nucleoside catabolism and embryo viability in the pregnant mouse. Teratology. 1992;45:91-103.
20. Weinberg K, Hershfield MS, Bastian J, et al. T lymphocyte ontogeny in adenosine deaminase-deficient severe combined immunodeficiency after treatment with polyethylene glycol-modified adenosine deaminase. J Clin Invest. 1993;92: 596-602.
21. Chan B, Wara D, Bastian J, et al. Long-term efficacy of enzyme replacement therapy for adenosine deaminase (ADA)-deficient severe combined immunodeficiency (SCID). Clin Immunol. 2005; 117:133-143.
22. Malacarne F. Benicchi T, Notarangelo LD. et al. Reduced thymic output, increased spontaneous apoptosis and oligoclonal B cells in polyethylene glycol-adenosine deaminase-treated patients. Eur J Immunol. 2005;35:3376-3386.
23. Fischer A, Landais P, Friedrich W, et al. European experience of bone-marrow transplantation for severe combined immunodeficiency. Lancet. 1990;336:850-854.
24. Hirschhorn R, Yang DR. Israni A, Huie ML, Ownby DR. Somatic mosaicism for a newly identified splice-site mutation in a patient with adenosine deaminase-deficient immunodeficiency and spontaneous clinical recovery. Am J Hum Genet. 1994;55:59-68.
25. ArigaT, Oda N, Yamaguchi K, et al. T-cell lines from 2 patients with adenosine deaminase (ADA) deficiency showed the restoration of ADA activity resulted from the reversion of an inherited mutation. Blood. 2001 ;97:2896-2899.
26. Arredondo-Vega FX. Santisteban I. Richard E. et al. Adenosine deaminase deficiency with mosaicism for a "second-site suppressor" of a splicing mutation: decline in revertant T lymphocytes during enzyme replacement therapy. Blood. 2002;99: 1005-1013.
27. Aiuti A. Vai S. Mortellaro A. et al. Immune reconstitution in ADA-SCID after PBL gene therapy and discontinuation of enzyme replacement. Nat Med. 2002;8:423-425.
28. Kohn DB, Hershfield MS, Carbonaro D, et al. T lymphocytes with a normal ADA gene accumulate after transplantation of transduced autologous umbilical cord blood CD34+ cells in ADA- deficient SCID neonates. Nat Med. 1998;4:775-780.
29. Aiuti A, Slavin S, Aker M, etal. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science. 2002; 296:2410-2413.
30. Gaspar HB, Bjorkegren E, Parsley K, et al. Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy after cessation of PEG-ADA and use of mild preconditioning. Mol Ther. 2006;14:505-513.